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OBJECTIVES: Romiplostim and eltrombopag are thrombopoietin receptor (TPOr)
agonists that promote megakaryocyte differentiation, proliferation and platelet
production. Both are orphan drugs mainly indicated for the treatment of adult
chronic idiopathic thrombocytopenic splenectomised patients who are refractory
to other treatments. Due to increasing platelet counts above the normal range may
represent a risk for thromboembolisms, we assessed whether TPOr agonists affect
thromboembolisms occurrence by a systematic review and meta-analysis of ran-
domised controlled trials (RCTs). METHODS: We searched PubMed, SCOPUS, Co-
chrane Central Register, regulatory agencies websites and publicly available regis-
tries of manufacturers (before January 2011). RCTs using romiplostim or
eltrombopag in at least one group were included. Absolute risk ratios (ARR) and
number needed to harm (NNH) were calculated to provide the population health
impact of the exposure. Relative risks (RR) were also provided. Data were pooled
using fixed-effects models. Heterogeneity was analysed using Cochran’s Q and I2
tests. RESULTS: Of 373 publications identified, 8 studies met the inclusion criteria
(n1,180 patients). In the TPOr agonist group, as compared with the control group
(e.g. placebo and/or standard of care), the meta-ARR for thromboembolisms was
1.8% (95% CI, 0.0% to 3.6%), and the meta-RR was 1.5 (95% CI, 0.7 to 3.3). Fifty-five
patients would have to be treated using TPOr agonists to produce thromboembo-
lisms in a patient (meta-NNH55). Non heterogeneity was found (Cochran’s Q test,
P  0.9; I2  0.0%). CONCLUSIONS: Although the small numbers reported, throm-
boembolisms should be considered as identified risks for these drugs. Healthcare
providers should use caution when administering these agents to patients with
known risk factors for thromboembolisms.
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OBJECTIVES: In a recent study in patients receiving warfarin, the initiation of st-
atins that are cytochrome P450 3A4 inhibitors was associated with an increased
risk of hospitalization for gastrointestinal bleeding in a Medicaid-insured popula-
tion, while the initiation of pravastatin was not. The present research attempted to
address some of the study limitations and assess whether similar findings are
applicable in a more recent, commercially-insured U.S. population. METHODS: A
retrospective matched-cohort design was used to compare baseline characteristics
and bleeding rates (e.g. gastrointestinal and non-gastrointestinal) between statin
and statin-free patients receiving warfarin concomitantly. Patients were matched
on a 1:1 ratio to balance patient characteristics, and a cox proportional hazard
model was used to control for confounding factors. The analyses were performed
for a matched “stabilized” population, i.e., patients who had been on warfarin for
6 months, did not have prior bleeding events, and did not use another statin
before the index date. For the matched “stabilized” populations, sub-group analy-
ses were performed on patients with atrial fibrillation, patients with venous throm-
bosis, patients age65 years, patients age75 years, prevalent/persistent warfarin
users, and by statin therapy. RESULTS: The method produced a small matched
sample of 6306 (3.82%) out of 123,328 statin users and 41,734 statin-free patients.
There were no statistically significant differences in bleeding rates between statin
users and statin-free patients. Results were similar for the sub-group analyses.
CONCLUSIONS: Using a claims database approach, high degree of heterogeneity
between statin users and non-users was found, resulting in a low matching rate.
This high degree of heterogeneity suggests that claims databases may be insuffi-
cient to detect/conclude as to differences in bleeding rates between statin versus
statin-free patients on warfarin. Alternative methods and additional clinical infor-
mation are needed to more accurately characterize bleeding rates in patients tak-
ing warfarin and a statin therapy concomitantly.
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OBJECTIVES: To determinate tobacco consumption effects on metabolic control
(biochemical/anthropometrics parameters), mortality and on CVE relapses inci-
dence during a 3 year follow-up. METHODS: Multicentric observational study un-
dertaken through the retrospective review of the medical records of patients at six
primary health-care centres and two hospitals. Inclusion criteria: subjects  30
years, who requested health care after suffering a CVE between 2003 and 2007.
Follow-up: 36 months. Groups: smokers, ex-smokers and non-smokers. Main mea-
sures: sociodemographics, morbidity, biochemical/anthropometrics parameters
(systolic and diastolic arterial pressure (mmHg), baseline glycaemia (mg/dL), body
mass index (kg/m2), serum triglycerides (mg/dL), total cholesterol (mg/dL), HDL-
cholesterol and LDL-cholesterol (mg/dL)), mortality and later CVE (ischemia, infarc-
tion, strokes, ischemic accident, peripheric artheriopathy). Statistical analysis: lo-
gistic regression model and Kaplan-Meier curves. RESULTS: 2,540 patients fulfilled
the inclusion criteria (smokers: 8.4%, exsmokers: 52.9%, non-smokers: 38.7%).
Mean age: 68.1 years old; men: 60.7%. By groups: patients showed a similar distri-
butions of comorbidities. 19.1% of smokers still smoked after the first CVE. Smoking
addiction was related with COPD (odds ratio, OR2.4; 95%CI: 1.7-3.5) and depres-
sive syndrome (OR1.5; 95%CI: 1.1-2.2). The smoking condition mean time was 24.4
(14.5) years for smokers and 4.2 (1.2) years for ex-smokers. Comparing baseline
(during hospitalization) and final (3 years follow-up), in the non-smokers group, all
parameters showed a significant reduction (8 to (8/8), in exsmokers (6/8) and in
smokers group only 4/8. All mortality causes (intrahospital and follow-up included)
was 4.2% (N106; 95%CI: 3.4-5.0%), in smokers: 4.2%; ex-smokers: 5.9% and non-
smokers: 1.8%; p0.001. Incidence rate of new CVE’s was 15.2% (95%CI: 13.8-16.6%)
in smokers: 18.6%; ex-smokers: 16.5%; non-smokers: 9.6%; p0.001. CVE’s were
present in 8.2%, 6.0% and 3.3% respectively, p0.05. CONCLUSIONS: In routine
medical practice, smokers compared with ex-smokers and with non-smokers still
support a high future risk of suffering CVE and higher mortality rates.
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OBJECTIVES: Syndrome of inappropriate antidiuretic hormone hypersecretion
(SIADH) is a common cause of hyponatremia contributing to 30-50% of hyponatre-
mia cases. Little is known of the influence of SIADH on healthcare resource utili-
zation. This study assessed the effect of SIADH on inpatient total and intensive care
unit (ICU) cost and length of stay (LOS), the likelihood of ICU admission, and 30-,
90-, and 180-day readmission. METHODS: The Premier hospital database was uti-
lized to identify US hospital inpatients discharged between January 1, 2007 and
June 30, 2009. Hyponatremic/SIADH patients were identified using primary or sec-
ondary ICD-9 codes (n430,731) and were matched to a control group (n430,731)
using exact matching on age, gender, provider region and 3M™ APR-DRG assign-
ment. Matching was further refined using propensity scores based on additional
patient and hospital covariates. Due to the contribution of congestive heart failure
and cirrhosis on hyponatremia development, these patients were excluded from
the analysis. The final analytic sample contained 65,973 SIADH patients and
407,874 non-hyponatremia/SIADH patients. Cost was analyzed using gamma re-
gression, LOS with negative binomial regression. ICU admission and hospital read-
mission were analyzed using multivariate logistic regression. RESULTS: In contrast
to non-SIADH patients, patients with SIADH had significantly higher total inpatient
cost (55.53%,CI52.53-58.60;p0.0001), ICU cost (38.07%;CI33.18-43.15;p.0001),
total LOS (45.11%,CI43.20-47.03;p0.0001), and ICU LOS (42.72%,CI38.36-47.23;
p0.0001). SIADH patients were significantly more likely to be admitted to the ICU
(OR2.131;p.0001), and readmitted at 30- (OR1.399;p0.0001), 90- (OR1.495;
p0.0001), and 180-days (OR1.459;p0.0001) in comparison with non-SIADH
patients. CONCLUSIONS: The presence of SIADH in hospitalized patients is signif-
icantly associated with increased total and ICU cost and LOS, likelihood of ICU
admission, and likelihood of readmission. Words  297
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OBJECTIVES: To compare treatment and 12-month outcomes after percutaneous
coronary intervention (PCI) of acute coronary syndrome (ACS) patients with and
without diabetes mellitus (DM). METHODS: Data were from APTOR, robust, pro-
spective, observational registries of 14 European countries from 2007-2009. Kaplan-
Meier (KM) estimates 12-months post-PCI were calculated for cardiovascular (CV)
event (unstable angina [UA], non-ST-elevation myocardial infarction [NSTEMI],
STEMI, urgent target vessel revascularization, acute heart failure, ischemic and
hemorrhagic strokes or CV death), bleeding, and mortality. RESULTS:A total of 21%
(N942) of patients had DM (median age: 66yrs) and 79% (N3603) did not have DM
(median age: 61 yrs). More patients with DM tended to be women (28% vs. 20%);
have hyperlipidaemia (64% vs. 47%) and hypertension (75% vs. 53%); and have prior
MI (28% vs. 18%) or PCI (27% vs. 16%) compared to patients without DM. For DM/
non-DM patients respectively, ACS presentation was 29%/21% with UA, 35%/30%
with NSTEMI, 36%/49% with STEMI; the use of glycoprotein IIb/IIIa inhibitors was
28%/33% and the use of 1 drug-eluting stent (DES) was 52%/39%. DM/non-DM
patients received similar treatment at hospital discharge and 12-months post-PCI
with the exception of ARB/ACE inhibitors at discharge (75% vs. 69%) and 12-months
post-PCI (79% vs. 71%). The respective DM/non-DM 12-month outcomes were 17.3%
(95% CI: 14.8-19.7%) vs. 13.8% (12.7-15.0%) for CV event, 3.0% (1.9-4.1%) vs. 2.7%
(2.2-3.2%) for bleeding, and 4.9% (3.5-6.3%) vs. 1.8% (1.4-2.3%) for mortality. Optimal
therapy (5 of the following at hospital discharge and at one-year post-PCI: aspirin,
clopidogrel, statins, beta-blockers, ARB/ACE-inhibitors, and exercise or diet) was
observed with 49%/42% of DM/non-DM patients. CONCLUSIONS: Patients with DM
more often received DES and ARB/ACE but still incur worse 12 month outcomes
compared to non-DM. Evidence-based prescribing post ACS-PCI is still sub-optimal
and newer more potent strategies should be considered for diabetic patients to
reduce the cardiovascular mortality and morbidity disparity.
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